{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-BZ3D0ICG/01907093-2025-4fa5-b1dd-7dee40969ad2/PDF","dcterms:extent":"173 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-BZ3D0ICG/3685d84e-46a1-4020-8a99-48aad071bcf9/TEXT","dcterms:extent":"23 KB"}],"edm:TimeSpan":{"@rdf:about":"1929-2026","edm:begin":{"@xml:lang":"en","#text":"1929"},"edm:end":{"@xml:lang":"en","#text":"2026"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:doc-BZ3D0ICG","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/urn:nbn:si:spr-a30mfzkp"},{"@xml:lang":"sl","#text":"Zdravniški vestnik"}],"dcterms:issued":"2004","dc:creator":["Majcen-Vivod, Božislava","Urlep-Šalinović, Veronika"],"dc:format":[{"@xml:lang":"sl","#text":"številka:4"},{"@xml:lang":"sl","#text":"letnik:73"},{"@xml:lang":"sl","#text":"str. 227-230"}],"dc:identifier":["ISSN:1318-0347","COBISSID_HOST:1526847","URN:URN:NBN:SI:doc-BZ3D0ICG"],"dc:language":"sl","dc:publisher":{"@xml:lang":"sl","#text":"Slovensko zdravniško društvo"},"dc:subject":[{"@xml:lang":"sl","#text":"Blood donors"},{"@xml:lang":"sl","#text":"Hepatitis"},{"@xml:lang":"sl","#text":"Jaundice"},{"@xml:lang":"sl","#text":"Krvodajalci"},{"@xml:lang":"sl","#text":"Questionnaire"},{"@xml:lang":"sl","#text":"Vprašalnik"},{"@xml:lang":"sl","#text":"Zlatenica"}],"dcterms:temporal":{"@rdf:resource":"1929-2026"},"dc:title":{"@xml:lang":"sl","#text":"Prevalenca hepatitisov A in B pri krvodajalcih z anamnezo zlatenice| Prevalence of hepatitis A and B among blood donors with history of jaundice|"},"dc:description":[{"@xml:lang":"sl","#text":"Background. Preventing transmission of infectious disease through blood transfusion presents one of the greatest challenges of transfusion medicine. All donations are monitored for syphilis since 1960, hepatitis B (HBsAg) since1970, aids (anti HIV) since 1986 and hepatitis C (anti-HCV) since 1993. Methods. Data on donors were found in the Datec computer program which is commonly used in all transfusion institutions in Slovenia. Results. Among 43,000 registered donors, 764 (1.78%) had a history of hepatitis. After testing, we found 666 of them positive (87.2%) for hepatitis A or B antibodies. 654 (85.6%) donors had hepatitis A antibodies and 98 (12.8%) had anti-HBc antibodies. Among these 98, 30 donors (30.6%) had no anti-HBs antibodies. 86 donors (11%) had antibodies against hepatitis A and B. Conclusions. After additional testing of donors for hepatitis B antibodies, we excluded 30 (0.069%) HBsAg negative, anti-HBc positive and anti-HBs negative donors with history of hepatitis"},{"@xml:lang":"sl","#text":"Izhodišča. Preprečitev prenosa nalezljivih bolezni s krvjo predstavlja pomembno področje v transfuzijski medicini. V Sloveniji testiramo kri na sifilis (anti-treponema pallidum) od leta 1960, hepatitis B (antigen virusa hepatitisa B - HBsAg) od leta 1970, aids (protitelesa proti virusu HIV - anti-HIV) od leta 1986 in hepatitis C (protitelesa proti virusu hepatitisa C -anti-HCV) od leta 1993. Po uvedbi vprašalnika leta 1994 na Oddelku za transfuziologijo in imunohematologijo v SB Maribor smo za vse krvodajalce, ki so na vprašalniku navedli, da so preboleli zlatenico, uvedli dodatna testiranja na protitelesa proti antigenu sredice virusa hepatitisa B (anti-HBc), protitelesa proti površinskemu antigenu virusa hepatitisa B (anti-HBs) in na protitelesa proti hepatitisu A (anti-HAV). V prispevku prikazujemo, koliko oseb z anamnezo zlatenice je prebolelo hepatitis A ali B, in koliko oseb po prebolelem hepatitisu B nima ustreznih zaščitnih protiteles anti-HBs. Metode. Podatke smo dobili iz računalniškega sistema DATEC, ki ga uporabljamo na transfuzijskih oddelkih po Sloveniji. Rezultati. Med 43.000 krvodajalci v letih 1994 do 2002 jih je 764 (1,78%) označilo na vprašalniku podatek, da so preboleli zlatenico. Med njimi jih je 666 (87,2%) imelo protitelesa proti hepatitisu A ali B. Protitelesa proti hepatitisu A smo odkrili pri 654 (85,6%) dajalcih in pri 98 (12,8%) smo odkrili protitelesa proti hepatitisu B. Med slednjimi 98 dajalci 30 (30,6%) oseb ni imelo protiteles anti-HBs, temveč le protitelo anti-HBc. 86 (11%) krvodajalcev je imelo hkrati protitelesa proti hepatitisu A in B. Zaključki. Z dodatnim testiranjem krvodajalcev, ki so preboleli zlatenico, smo tako odkrili 30 (0,069%) HBsAg negativnih anti-HBc pozitivnih krvodajalcev brez ustreznih protiteles anti-HBs"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:doc-BZ3D0ICG","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:doc-BZ3D0ICG"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:doc-BZ3D0ICG/01907093-2025-4fa5-b1dd-7dee40969ad2/PDF"},"edm:rights":{"@rdf:resource":"http://creativecommons.org/licenses/by-nc/4.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Slovensko zdravniško društvo"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:doc-BZ3D0ICG/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:doc-BZ3D0ICG"}}}}